- Design
- Assay development and validation with clinical cohort analysis
- Population
- 121 children with biopsy-confirmed minimal change disease or primary FSGS, plus controls
- Primary outcome
- Agreement with immunoprecipitation–Western blot; association with relapse
- Effect
- Concordance 86.8% (kappa 0.714); positivity 41.3% vs 28.1%
A study in Kidney International (21 September) developed an automated chemiluminescence immunoassay for anti-nephrin IgG and tested it in 121 children with biopsy-proven minimal change disease or primary FSGS, alongside disease controls and healthy individuals, against immunoprecipitation–Western blot as reference.
The two methods agreed in 87% of samples (kappa 0.71). The automated assay detected antibodies more often (41% against 28%). Antibody positivity was associated with heavier proteinuria, lower albumin and steroid sensitivity; higher levels predicted shorter relapse-free survival, and positivity during remission was linked to relapse within three months, with risk rising with titre.
Anti-nephrin antibodies are reshaping how minimal change disease and some FSGS are understood — as autoimmune podocytopathies. A scalable assay brings testing closer to routine use, but it is not yet standardised or widely available, and its role in guiding treatment has not been tested.
- The automated assay agreed with the reference method in 87% of samples
- Antibody positivity in remission was linked to relapse within three months
- Higher titres predicted shorter relapse-free survival
- Not yet a basis for treatment decisions; availability is limited
Why it matters
A measurable antibody could let clinicians anticipate relapse rather than react to it.
Don't overread it
A single-centre paediatric assay study — monitoring with it has not been shown to improve outcomes.
The statistics, in plain English
A kappa of 0.71 indicates substantial agreement beyond chance. Detecting more positives than the reference could mean higher sensitivity or more false positives; the antigen inhibition tests support the former.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free